162 related articles for article (PubMed ID: 38347759)
21. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
Navarese EP; Kolodziejczak M; Schulze V; Gurbel PA; Tantry U; Lin Y; Brockmeyer M; Kandzari DE; Kubica JM; D'Agostino RB; Kubica J; Volpe M; Agewall S; Kereiakes DJ; Kelm M
Ann Intern Med; 2015 Jul; 163(1):40-51. PubMed ID: 25915661
[TBL] [Abstract][Full Text] [Related]
22. Considerations and limitations of buprenorphine prescribing for opioid use disorder in the intensive care unit setting: A narrative review.
Erstad BL; Glenn MJ
Am J Health Syst Pharm; 2024 Mar; 81(6):171-182. PubMed ID: 37979138
[TBL] [Abstract][Full Text] [Related]
23. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.
Pérez de Isla L; Ray KK; Watts GF; Santos RD; Alonso R; Muñiz-Grijalvo O; Diaz-Diaz JL; Badimon L; Catapano AL; Mata P
Atherosclerosis; 2019 Jul; 286():40-45. PubMed ID: 31100618
[TBL] [Abstract][Full Text] [Related]
24. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
25. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials.
Bai J; Gong LL; Li QF; Wang ZH
J Clin Lipidol; 2018; 12(2):277-291.e3. PubMed ID: 29428832
[TBL] [Abstract][Full Text] [Related]
27. PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia.
Ito MK; Santos RD
J Clin Pharmacol; 2017 Jan; 57(1):7-32. PubMed ID: 27195910
[TBL] [Abstract][Full Text] [Related]
28. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
[TBL] [Abstract][Full Text] [Related]
29. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
30. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
[TBL] [Abstract][Full Text] [Related]
31. Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies.
Oleaga C; Shapiro MD; Hay J; Mueller PA; Miles J; Huang C; Friz E; Tavori H; Toth PP; Wójcik C; Warden BA; Purnell JQ; Duell PB; Pamir N; Fazio S
J Am Coll Cardiol; 2021 Oct; 78(14):1437-1449. PubMed ID: 34593126
[TBL] [Abstract][Full Text] [Related]
32. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.
Descamps OS; Fraass U; Dent R; März W; Gouni-Berthold I
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28750477
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
[TBL] [Abstract][Full Text] [Related]
34. Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Chen Q; Wu G; Li C; Qin X; Liu R; Zhang M
Am J Cardiovasc Drugs; 2020 Aug; 20(4):343-353. PubMed ID: 31823301
[TBL] [Abstract][Full Text] [Related]
35. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
36. Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia.
Jackson CL; Deng Y; Yao X; Van Houten H; Shah ND; Kopecky S
J Clin Lipidol; 2021; 15(2):339-346. PubMed ID: 33419720
[TBL] [Abstract][Full Text] [Related]
37. Clinical Pharmacy Services in a Multidisciplinary Specialty Pain Clinic.
Semerjian M; Durham MJ; Mirzaian E; Lou M; Richeimer SH
Pain Pract; 2019 Mar; 19(3):303-309. PubMed ID: 30403432
[TBL] [Abstract][Full Text] [Related]
38. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
Gouni-Berthold I; Descamps OS; Fraass U; Hartfield E; Allcott K; Dent R; März W
Br J Clin Pharmacol; 2016 Dec; 82(6):1412-1443. PubMed ID: 27478094
[TBL] [Abstract][Full Text] [Related]
39. Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels.
Ye Q; Svatikova A; Meeusen JW; Kludtke EL; Kopecky SL
Am J Cardiol; 2020 Aug; 128():163-167. PubMed ID: 32650914
[TBL] [Abstract][Full Text] [Related]
40. Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort.
Saborowski M; Dölle M; Manns MP; Leitolf H; Zender S
Cardiol J; 2018; 25(1):32-41. PubMed ID: 29168543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
